Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis

Banerjee, 2009, Vildagliptin in clinical practice: a review of literature, Expert Opin Pharmacother, 10, 2745, 10.1517/14656560903302265 Kim, 2008, The role of incretins in glucose homeostasis and diabetes treatment, Pharmacol Rev, 60, 470, 10.1124/pr.108.000604 Utzschneider, 2008, The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose, Diabetes Care, 31, 108, 10.2337/dc07-1441 Azuma, 2008, Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes, J Clin Endocrinol Metab, 93, 459, 10.1210/jc.2007-1369 Miura, 2010, Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats, Horm Metab Res, 42, 731, 10.1055/s-0030-1261929 Vlassara, 1996, Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors, Diabetes Suppl, 3, S65, 10.2337/diab.45.3.S65 Brownlee, 1998, Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications, N Engl J Med, 318, 1315 Rahbar, 2007, Novel inhibotrs of glycation and AGE formation, Cell Biochem Biophys, 48, 147, 10.1007/s12013-007-0021-x Yan, 2010, The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature, Circ Res, 106, 842, 10.1161/CIRCRESAHA.109.212217 Yamagishi, 2009, Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease, Pharmacol Res, 60, 174, 10.1016/j.phrs.2009.01.006 Yamagishi, 2005, Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy, Curr Pharm Des, 11, 2279, 10.2174/1381612054367300 Jandeleit-Dahm, 2008, The role of AGEs in cardiovascular disease, Curr Pharm Des, 14, 979, 10.2174/138161208784139684 Yamagishi, 2008, Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications, Expert Opin Investig Drugs, 17, 983, 10.1517/13543784.17.7.983 Yamagishi, 2008, Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication, Curr Pharm Des, 14, 487, 10.2174/138161208783597416 Yamagishi, 2010, Smooth muscle cell pathophysiology and advanced glycation end products (AGEs), Curr Drug Targets, 11, 875, 10.2174/138945010791320827 Ishibashi, 2010, Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression, Biochem Biophys Res Commun, 391, 1405, 10.1016/j.bbrc.2009.12.075 Takeuchi, 2000, Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo, Mol Med, 6, 114, 10.1007/BF03401779 Miura K, Kitahara Y, Kajioka T, Takeuchi M, Yamagishi S. Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker fatty rats by suppressing advanced glycation end product receptor axis. Horm Metab Res, in press. Yamagishi, 2007, Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats, Ophthalmic Res, 39, 92, 10.1159/000099244 Yamagishi, 2006, Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression, J Biol Chem, 281, 20213, 10.1074/jbc.M602110200 Ide, 2010, Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation, Microvasc Res, 80, 227, 10.1016/j.mvr.2010.03.015 Matsui, 2010, Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression, Pharmacol Res, 61, 34, 10.1016/j.phrs.2009.07.004 Yamagishi, 1998, Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells, Diabetologia, 41, 1435, 10.1007/s001250051089 Matsui, 2009, Nifedipine a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation, Biochem Biophys Res Commun, 385, 269, 10.1016/j.bbrc.2009.05.061 Inagaki, 2003, Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation, Diabetologia, 46, 284, 10.1007/s00125-002-1013-4 Yamagishi, 2003, Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells, Kidney Int, 63, 464, 10.1046/j.1523-1755.2003.00752.x Yamagishi, 2002, Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells, J Biol Chem, 277, 20309, 10.1074/jbc.M202634200 Okamoto, 2002, Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin, FASEB J, 16, 1928, 10.1096/fj.02-0030fje Burkey, 2005, Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats, J Pharmacol Exp Ther, 315, 688, 10.1124/jpet.105.087064 Soro-Paavonen, 2008, Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes, Diabetes, 57, 2461, 10.2337/db07-1808